[go: up one dir, main page]

PE20240237A1 - Inhibidores heterociclicos de la cinasa rip1 - Google Patents

Inhibidores heterociclicos de la cinasa rip1

Info

Publication number
PE20240237A1
PE20240237A1 PE2023002567A PE2023002567A PE20240237A1 PE 20240237 A1 PE20240237 A1 PE 20240237A1 PE 2023002567 A PE2023002567 A PE 2023002567A PE 2023002567 A PE2023002567 A PE 2023002567A PE 20240237 A1 PE20240237 A1 PE 20240237A1
Authority
PE
Peru
Prior art keywords
independently
compounds
methyl
inhibitors
linker
Prior art date
Application number
PE2023002567A
Other languages
English (en)
Inventor
Somasekhar Bhamidipati
Kyle Defrees
Simon Shaw
Vanessa Taylor
Original Assignee
Rigel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals Inc filed Critical Rigel Pharmaceuticals Inc
Publication of PE20240237A1 publication Critical patent/PE20240237A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Referido a compuestos heterociclicos de formula (I), o una sal, N-oxido, solvato, tautomero o estereoisomero farmaceuticamente aceptable de este; en donde el anillo B es heteroarilo de 5 o 6 miembros tal como pirazolilo o piridinilo; cada R1 es independientemente halogeno o un grupo enlazador-R6, en donde el enlazador es una union o Ra, siempre que Ra no sea H o D, y R6 es heterociclilo, Rb, -C(Rf)3, o -C(Rf)=C(Rf)2; R2 es Ra, R3 es Ray pueden ser H; cada R4 es independientemente Re; L es un heteroatomo o Ra, siempre que Ra no sea H o D; X es CH2 u O; Z es heteroarilo; m es 1-4; n es 0-2; Ra es independientemente H o D; Rb es independientemente -OH, -SH, -ORc, entre otros. Dichos compuestos son inhibidores de la proteina 1 cinasa que interactua con el receptor (RIP1). Un compuesto seleccionado es (S)-4-((6-fluoropiridin-2-il)metil)-N-(7-(3-hidroxi-3-metilbut-1-in-1-il)-5-metil-4-oxo-2,3,4,5- tetrahidrobenzo[b][1,4]oxazepin-3-il)-1H-pirazol-1-carboxamida. Tambien se refiere a metodos para preparar dichos compuestos y una composicion farmaceutica que los comprende, siendo utiles para tratar o prevenir una enfermedad o asociada a RIP 1, tal como un trastorno inflamatorio o inmunorregulador.
PE2023002567A 2021-03-11 2022-03-10 Inhibidores heterociclicos de la cinasa rip1 PE20240237A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163159970P 2021-03-11 2021-03-11
PCT/US2022/019744 WO2022192533A1 (en) 2021-03-11 2022-03-10 Heterocyclic rip1 kinase inhibitors

Publications (1)

Publication Number Publication Date
PE20240237A1 true PE20240237A1 (es) 2024-02-16

Family

ID=81327717

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023002567A PE20240237A1 (es) 2021-03-11 2022-03-10 Inhibidores heterociclicos de la cinasa rip1

Country Status (19)

Country Link
US (1) US12156880B2 (es)
EP (1) EP4304713A1 (es)
JP (1) JP2024509466A (es)
KR (1) KR20230144575A (es)
CN (1) CN117083270A (es)
AR (1) AR125587A1 (es)
AU (1) AU2022232927B2 (es)
BR (1) BR112023018167A2 (es)
CA (1) CA3211778A1 (es)
CL (1) CL2023002704A1 (es)
CO (1) CO2023012077A2 (es)
CR (1) CR20230438A (es)
DO (1) DOP2023000186A (es)
EC (1) ECSP23068893A (es)
IL (1) IL305456A (es)
MX (1) MX2023010624A (es)
PE (1) PE20240237A1 (es)
TW (1) TW202300490A (es)
WO (1) WO2022192533A1 (es)

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US4738851A (en) 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US4882150A (en) 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US5521222A (en) 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
DE69009946T2 (de) 1989-12-04 1994-11-03 Searle & Co System zur transdermalen Albuterol Applikation.
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5077033A (en) 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
DE69228827T2 (de) 1991-12-18 1999-10-21 Minnesota Mining And Mfg. Co., Saint Paul Mehrschichtige sperrstrukturen
ATE132381T1 (de) 1992-01-29 1996-01-15 Voelkl Franz Ski Ballspielschläger, insbesondere tennisschläger
IL114193A (en) 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US6197934B1 (en) 1998-05-22 2001-03-06 Collagenesis, Inc. Compound delivery using rapidly dissolving collagen film
US20090099242A1 (en) 2007-08-15 2009-04-16 Cuny Gregory D Heterocyclic inhibitors of necroptosis
US8922322B2 (en) * 2012-08-31 2014-12-30 Delta Electronics, Inc. Combined structure of hollow bobbin and conductive sheet, hollow bobbin, and conductive sheet
TWI638815B (zh) * 2013-02-15 2018-10-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類（一）
US9725452B2 (en) 2013-03-15 2017-08-08 Presidents And Fellows Of Harvard College Substituted indoles and pyrroles as RIP kinase inhibitors
KR20170042595A (ko) * 2014-08-21 2017-04-19 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 의약으로서의 rip1 키나제 억제제로서의 헤테로시클릭 아미드
US10287280B2 (en) 2015-02-13 2019-05-14 Glaxosmithkline Intellectual Property Development Limited Crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide
MA42302A (fr) * 2015-07-02 2018-05-09 Hoffmann La Roche Lactames bicycliques et leurs méthodes d'utilisation
EP3362449B1 (en) 2015-10-13 2021-06-16 Institut National de la Santé et de la Recherche Médicale (INSERM) Sibiriline derivatives for use for preventing and/or treating disorders associated with cellular necroptosis
WO2017069279A1 (ja) 2015-10-23 2017-04-27 武田薬品工業株式会社 複素環化合物
WO2017109724A1 (en) 2015-12-21 2017-06-29 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
IL287136B2 (en) 2016-02-05 2023-09-01 Denali Therapeutics Inc Receptor inhibitors - interacting with protein kinase 1
WO2018073193A1 (en) 2016-10-17 2018-04-26 F. Hoffmann-La Roche Ag Bicyclic pyridone lactams and methods of use thereof
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
CN110573504A (zh) 2017-02-27 2019-12-13 葛兰素史克知识产权开发有限公司 作为激酶抑制剂的杂环酰胺
WO2019213445A1 (en) 2018-05-03 2019-11-07 Rigel Pharmaceuticals, Inc. Rip1 inhibitory compounds and methods for making and using the same
PT3788044T (pt) 2018-05-03 2023-08-31 Rigel Pharmaceuticals Inc Compostos inibidores de rip1 e métodos para preparar e usar os mesmos
CN111138448B (zh) * 2018-11-02 2022-08-02 中国科学院上海药物研究所 抑制rip1激酶的杂环酰胺及其用途
WO2020088194A1 (zh) * 2018-11-02 2020-05-07 中国科学院上海药物研究所 抑制rip1激酶的杂环酰胺及其用途
JP2022546520A (ja) * 2019-09-06 2022-11-04 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｒｉｐ１阻害化合物ならびにそれを作製および使用するための方法
JOP20220056A1 (ar) 2019-09-06 2023-01-30 Rigel Pharmaceuticals Inc مركبات rip1 تثبيطية وطرق عملها واستخدامها
IL292536A (en) 2019-11-07 2022-06-01 Rigel Pharmaceuticals Inc Heterocyclic rip1 inhibitory compounds
AU2020391425A1 (en) * 2019-11-26 2022-06-16 Board Of Regents, The University Of Texas System Inhibitors of Receptor Interacting Protein Kinase 1 for the treatment of disease

Also Published As

Publication number Publication date
CA3211778A1 (en) 2022-09-15
AR125587A1 (es) 2023-08-02
EP4304713A1 (en) 2024-01-17
ECSP23068893A (es) 2023-10-31
AU2022232927B2 (en) 2025-02-27
AU2022232927A1 (en) 2023-08-17
CN117083270A (zh) 2023-11-17
KR20230144575A (ko) 2023-10-16
US20220296608A1 (en) 2022-09-22
US12156880B2 (en) 2024-12-03
JP2024509466A (ja) 2024-03-01
CL2023002704A1 (es) 2024-03-22
BR112023018167A2 (pt) 2023-10-31
CR20230438A (es) 2024-01-16
TW202300490A (zh) 2023-01-01
IL305456A (en) 2023-10-01
WO2022192533A1 (en) 2022-09-15
DOP2023000186A (es) 2023-11-30
CO2023012077A2 (es) 2024-01-15
MX2023010624A (es) 2023-11-28

Similar Documents

Publication Publication Date Title
PE20240584A1 (es) Agonistas del receptor de glp-1 y usos de los mismos
PE20220592A1 (es) Inhibidores de la autofagia de heteroarilaminopirimidina amida y metodos de uso de estos
PE20221336A1 (es) Compuestos triciclicos sustituidos
PE20230249A1 (es) Compuestos de heteroarilo biciclicos y usos de estos
JP5923560B2 (ja) 新規なピロール化合物、その調製方法及びそれらを含む医薬組成物
PE20220931A1 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
PE20221457A1 (es) Degradadores de moleculas pequenas de helios y procedimientos de uso
JP2019500352A5 (es)
PE20191613A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
AR113299A1 (es) Compuestos de isoindolina
CO2018004800A2 (es) Antagonistas del receptor muscarinico 4 y metodos de uso.
PE20191647A1 (es) Acidos propionicos 3-sustituidos como inhibidores de la integrina alfa v
ES2586527T9 (es) Compuestos heterocíclicos y uso de los mismos como moduladores del receptor de tirosina quinasas de tipo III
EA201891463A1 (ru) ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРАЗИН-4-ИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ (JAK)
CO2022001853A2 (es) Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr
AR109958A1 (es) Lactamas bicíclicas de piridona y sus métodos de uso
PE20231311A1 (es) Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos
RU2007134428A (ru) Производные 1 н-имидазола как модуляторы рецептора каннабиноидов св2
AR116880A1 (es) Compuestos de pirimidinodiona bicíclicos sustituidos con tetrahidropirano, forma polimórfica del mismo y el uso de los mismos para el tratamiento del hcm
JP2016540792A5 (es)
EA022420B1 (ru) Гетероциклические ингибиторы глутаминилциклазы (qc, ec 2.3.2.5)
PE20210176A1 (es) Inhibidores de arginasa y sus metodos de uso
AR117229A1 (es) Compuestos heteroaromáticos como inhibidores de vanina
AR017189A1 (es) Antagonistas del receptor de trombina triciclico sustituido, composicion farmaceutica que lo contiene y su uso para la manufactura de un medicamento
AR057377A1 (es) Derivados de cicloheptapiridina como inhibidores de tirosina quinasa. composiciones farmaceuticas